TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
LAVA Therapeutics ( (LVTX) ) just unveiled an update.
LAVA Therapeutics announced that following the expiration of a subsequent offering period on November 20, 2025, approximately 91.1% of its outstanding shares were validly tendered. The company also voluntarily delisted its shares from Nasdaq, with trading suspended on November 21, 2025, and plans to terminate its reporting obligations under the Exchange Act by December 1, 2025. Additionally, Stephen Hurly and Fred Powell ceased to be executive officers of the company effective November 21, 2025.
The most recent analyst rating on (LVTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.
Spark’s Take on LVTX Stock
According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.
LAVA Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. While technical indicators show some positive trends, the company’s negative valuation metrics further weigh down the score.
To see Spark’s full report on LVTX stock, click here.
More about LAVA Therapeutics
Average Trading Volume: 346,591
Technical Sentiment Signal: Buy
Current Market Cap: $47.61M
For detailed information about LVTX stock, go to TipRanks’ Stock Analysis page.